Novo Nordisk A/s

Symphogen A/s

Finn C Wiberg

So Slashedren Bjo Slashedrn

Lars Soegaard Nielsen

Chiou-Ying Yang

John S Haurum

Jacqueline Sharon

Else Marie Nicolaisen

Anne Bondgaard Tolstrup

Dietmar Weilguny

Helle Fabricius W&ouml;ldike

Vincent W Coljee

Christian Muller

Lars S&oslash;egaard Nielsen

Richard Woodbury

Christian Müller

Christian Mueller

The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a library of variant nucleic acid sequences, wherein each call in the collection is transfected with and capable of expressing one member of the library, which encodes a distinct member of a polyclonal protein that binds a particular antigen and which is located at the same single site in the genome of individual cells in said collection, wherein said nucleic acid sequence is not naturally associated with said cell in the collection. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The present method is suitable for manufacturing recombinant polyclonal antibodies, thereby making available a superior replacement of plasma-derived therapeutic immunoglobulin products.

Method for manufacturing recombinant polyclonal proteins

The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the collection, which encodes a distinct member of a polyclonal protein. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence is introduced into the cells by transfection with a collection of vectors. The present method is suitable for manufacturing recombinant polyclonal antibodies for therapeutic uses.

Method for manufacturing a recombinant polyclonal protein

Disclosed is a method for high efficiency release of recombinant proteins in eukaryotic cells and more specifically, for enhancing the secretion of Factor VII by co-expression of kex2 endoprotease with FVII in cells of mammalian origin.

Method for the production of factor VII

This application relates to modified blood coagulation factors, DNA sequences coding for such modified factors and a process for their production.

Modified factor VII/VIIa

Growing community of inventors

Farum, Denmark

Finn C Wiberg